Novel cell metabolism regulating compounds and their uses

Abstract

A class of compounds that bind to fatty acid binding protein (FABP4) and regulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising such compounds in combination with a pharmaceutically acceptable diluent or carrier, and optionally further combined with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of drugs for treating diseases that act on FABP4.

Description

[0001] Cross - reference to related applications

[0002] This application claims the priority of U.S. Provisional Patent Application S / N 62 / 963,508, filed on January 20, 2020, the entire content of which is incorporated herein by reference in its entirety. Technical field

[0003] The field of embodiments of the present invention relates to new compounds for treating or preventing diseases related to metabolism and inflammation, including but not limited to type 2 diabetes, atherosclerosis, intracranial atherosclerotic disease, Alzheimer's disease, non - alcoholic steatohepatitis, obesity, cardiovascular disease, asthma, cancer, and other diseases. The compounds of the present invention specifically interact with fatty acid - binding protein 4 (FABP4) and improve glucose consumption in adipocytes. Background art

[0004] Fatty acid - binding proteins (FABPs) are a family of proteins that reversibly bind free fatty acids and other lipid molecules and facilitate their transport in cells. To date, nine different FABP subtypes have been identified in mammals. FABP subtypes exhibit different expression patterns in different tissues. Fatty acid - binding protein 4 (FABP4), also often referred to as aP2 in the literature, is mainly expressed in adipocytes and macrophages and mediates key metabolic and inflammatory pathways in these cells, such as lipid storage and degradation, signal transduction, and eicosanoid production. In addition, FABP4 is also secreted into the plasma and is considered an adipose - derived factor that regulates whole - body glucose homeostasis.

[0005] Gene knockout studies in mice have provided some insights into the tissue-specific and systemic functions of FABP4. Importantly, when mice carrying a homozygous deletion of the FABP4 gene were fed a long-term high-fat diet, they gained weight comparable to wild-type mice but were not affected by hyperglycemia and insulin tolerance. See G.S. Hotamisligil et al., “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in Ap2, the Adipocyte Fatty Acid Binding Protein,” Science, 1996, 274(5291), pp. 1377-1379, doi:10.1126 / science.274.5291.1377. Additionally, FABP4 deficiency significantly protected apolipoprotein E (ApoE)-knockout mice from atherosclerosis, a phenotype attributed to FABP4 regulation of inflammatory pathways in macrophages. See L. Makowski et al., “Lack of Macrophage Fatty-Acid-Binding Protein aP2 Protects Mice Deficient in Apolipoprotein E Against Atherosclerosis,” Nat. Med., 2001, 7(6), pp. 699-705, doi:10.1038 / 89076. Expression of FABP4 has also been detected in airway epithelial cells, and FABP4 deficiency has been demonstrated to be protective in a mouse model of allergic pulmonary inflammation. See B.O.V. Shum et al., “The Adipocyte Fatty Acid-Binding Protein aP2 is Required in Allergic Airway Inflammation,” J. Clin. Invest., 2006, 116(8), pp. 2183-2192, doi:10.1172 / JCI24767.

[0006] Several reports have been published in the literature linking FABP4 expression levels and functions to many human pathologies. For example, a reduced risk of type 2 diabetes and coronary heart disease has been observed in individuals carrying a genetic variant in the promoter region of FABP4 (rs77878271) that results in reduced expression of the gene. See G. Tuncman et al., “A Genetic Variant at the Fatty Acid-binding Protein aP2 Locus Reduces the Risk for Hypertriglyceridemia, Type 2 Diabetes, and Cardiovascular Disease,” Proc. Natl. Acad. Sci. USA, 2006, 103(18), pp. 6970 - 5, doi:10.1073 / pnas.0602178103. In an independent study, the same polymorphism was also associated with a reduced clinical manifestation of atherosclerotic disease. See J. Saksi et al., “Low-Expression Variant of Fatty Acid-Binding Protein 4 Favors Reduced Manifestations of Atherosclerotic Disease and Increased Plaque Stability,” Circ. Cardiovasc. Genet., 2014, 7(5), pp. 588 - 98, doi:10.1161 / CIRCGENETICS.113.000499. In addition, triple-negative breast cancer patients with a single nucleotide polymorphism in the 3’ untranslated region (UTR) of FABP4 (rs1054135 - GG genotype) that results in reduced FAB4 expression are associated with a reduced risk of disease progression and an extended disease-free survival. See W. Wang et al., “A Single-Nucleotide Polymorphism in the 3′-UTR Region of the Adipocyte Fatty Acid Binding Protein 4 Gene is Associated with Prognosis of Triple-Negative Breast Cancer,” Oncotarget., 2016, 7(14), pp. 18984 - 18998, doi:10.18632 / oncotarget.7920. In addition, increased FABP4 expression has been observed in preeclamptic placentas, and it has been proposed that increased FABP4 expression plays a role in the pathogenesis of preeclampsia.See Y. Yan et al., “Increased Expression of Fatty Acid Binding Protein 4 in Preeclamptic Placenta and its Relevance to Preeclampsia,” Placenta, 2016, 39, pp. 94 - 100, https: / / doi.org / 10.1016 / j.placenta.2016.01.014. Similarly, granulosa cells from patients with polycystic ovary syndrome also show increased FABP4 expression, which is associated with the clinical features of the disease. See W. Hu et al., “Expression and Regulation of Adipocyte Fatty Acid Binding Protein in Granulosa Cells and its Relation with Clinical Characteristics of Polycystic Ovary Syndrome,” Endocrine, 2011, 40(2), pp. 196 - 202, doi:10.1007 / s12020-011-9495-9. Collectively, these studies demonstrate the positive role of FAPB4 in regulating whole-body metabolism and inflammation and suggest that pharmacological targeting of FABP4 could be used as a strategy for treating various diseases associated with FABP4 function.

[0007] Adipocytes play an important role in whole-body glucose homeostasis. One of their main functions is to absorb excess glucose from the plasma and store it in the form of lipids. Due to metabolic stress and inflammation, adipocyte dysfunction often gives rise to complications such as hyperglycemia and insulin tolerance. Notably, FABP4-deficient mice exhibit increased glucose deposition in adipose tissue. Adipocytes isolated from these animals showed a significantly increased rate of glucose conversion to fatty acids compared to their wild-type counterparts. See S. Shaughnessy et al., "Adipocyte Metabolism in Adipocyte Fatty Acid Binding Protein Knockout Mice (Ap2- / -) After Short-Term High-Fat Feeding: Functional Compensation by the Keratinocyte [Correction Of Keritinocyte] Fatty Acid Binding Protein," Diabetes, 2000, 49(6), pp. 904-911, https: / / doi.org / 10.2337 / diabetes.49.6.904. Thus, glucose consumption in adipocytes can be increased by targeting FABP4.

[0008] While the literature and certain prior art patent applications (e.g., WO 00 / 47734, WO 00 / 15229, WO 00 / 15230, WO 02 / 40448, WO 01 / 54694, WO 00 / 59506, and WO 2004 / 063156) have generally provided various introductions to the concept of FABP inhibition, particularly the concept of FABP4 inhibition, the discussions in these prior art documents do not provide solutions to all unmet needs as does the present invention. Specifically, the present invention discloses a new class of compounds that bind to FABP4 and modulate adipocyte metabolism to promote glucose utilization. Summary of the Invention

[0009] In one embodiment, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof:

[0010]

[0011] wherein R 1 and R 6 -R 9 are each independently -H, -CN, -COOH, -CONH 2 , B(OR a )2 , acid isostere, halogen, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0012] wherein R in B(OR a ) 2 is H or alkyl, a wherein B in B(OR

[0013] ) a ) 2 is boron,

[0014] wherein n in C n is 1 - 10,

[0015] wherein R 2 -R 5 are each independently -H, -CN, -COOH, -COOMe, -CONH 2 , B(OR a ) 2 , acid isostere, halogen, -CONHOH, -NH-SO 2 -Cι-C 6 -alkyl, -NHSO 2 Ar, C n alkyl, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0016] wherein -NHSO 2Ar in Ar is selected from: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4,-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene,

[0017] wherein C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl and C n heterocycloalkyl are each unsubstituted or substituted with 1 - 5 substituents,

[0018] wherein each substituent is the same or different,

[0019] wherein each substituent is selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl and -C q -U-C q ,

[0020] wherein each q in -C q -U-C q is independently from 0 to 10,

[0021] wherein each q in -C q -U-C qU is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), any one of

[0022] wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0023] wherein each R in N(R 1 )(R 1 ) 1 is unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different substituents, and the substituents are independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl,

[0024] wherein Q is a bond or O,

[0025] wherein X is C, N, O or S, and if X is O or S, then R 6 does not exist,

[0026] wherein "A" is a saturated or unsaturated ring represented by ,

[0027] wherein Y, T, W and Z are independently a bond, C, N, O, alkyl having 1 to 4 carbon atoms or alkenyl having 1 to 4 carbon atoms, and

[0028] wherein n is 0, 1, 2 or 3.

[0029] In one embodiment, the present invention includes a compound of formula I, wherein R 1 and R 2 , R 2 and R3 , R 3 and R 4 , R 4 and R 5 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 in at least one set of which are bonded to form a fused heteroaryl or fused heterocycloalkyl.

[0030] In a further embodiment, the invention can be a compound of formula II or a pharmaceutically acceptable salt or ester thereof:

[0031]

[0032] wherein R 1 and R 6 -R 9 are each independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halogen, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0033] wherein R a in B(OR 2 ) a is H or alkyl,

[0034] wherein B in B(OR a ) 2 is boron,

[0035] wherein n in C n is 1 - 10,

[0036] wherein R 2 -R 5 are each independently -H, -CN, -COOH, -COOMe, -CONH 2 , B(OR a ) 2 , an acid isostere, a halogen, -CONHOH, -NH-SO 2 -Cι-C 6 -alkyl, -NHSO 2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n heterocycloalkyl,

[0037] wherein -NHSO 2 Ar in Ar is selected from: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4,-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene,

[0038] wherein C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl and C n heterocycloalkyl are each unsubstituted or substituted with 1-5 substituents,

[0039] wherein each substituent is the same or different,

[0040] wherein each substituent is selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl and -C q -U-C q ,

[0041] wherein -C q -U-C q each q in is independently from 0 to 10,

[0042] wherein -C q -U-C q U in is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ),

[0043] wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0044] wherein each R in N(R 1 )(R 1 ) 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents, which may be the same or different and are independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl,

[0045] wherein Q is a bond or O,

[0046] wherein X is C, N, O or S, and if X is O or S, then R 6 is absent,

[0047] wherein X is C, N, O or S, and

[0048] wherein n is 0, 1, 2 or 3.

[0049] In some embodiments, the present invention includes compounds of formula II, wherein the heterocycloalkyl is attached via R 7 , R 8or R 9 are bonded together to form the following substances:

[0050]

[0051] Other embodiments of the present invention include compounds of formula III or pharmaceutically acceptable salts or esters thereof:

[0052]

[0053] wherein R 1 is selected from: -CN, alkyl, -H, halogen, 2 H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxy-alkyl, hydroxy-aryl, (aryl)alkyl, C(O)OH, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl, and C(O)NH 2 ,

[0054] wherein R 3 and R 4 are each independently -H, halogen, C n alkyl, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, C n heterocycloalkyl and -C q -U-C q ,

[0055] wherein n in C n is 1 - 10,

[0056] wherein each q in -C q -U-C q is independently 0 to 10,

[0057] wherein U in -C q -U-C q is any one of O, S, SO 2 or N(R 1 )(R 1 ),

[0058] wherein N(R 1 )(R 1each R in 1 is independently hydrogen,

[0059] wherein C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl and C n heterocycloalkyl are each unsubstituted or substituted with 1 - 5 substituents,

[0060] wherein each substituent is the same or different,

[0061] wherein each substituent is selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl -, (amino) alkoxy -, - alkyl, - alkenyl, - alkynyl, alkoxy -, hydroxy, - alkylhydroxy, aryloxy -, - alkyl(aryl), (alkoxyalkyl) amino -, - aryl, - aryl(halo), - heteroaryl, hydroxy - alkyl -, hydroxy - aryl -, (aryl) alkyl -, - S(O) 2 - alkyl, - S(O) 2 - aryl and - C(O)alkyl,

[0062] wherein R 6 is independently H or alkyl,

[0063] wherein R 7 and R 8 are each independently hydrogen, 2 H, fluoro or alkyl,

[0064] wherein R 6 and R 7 combine with adjacent R groups to form a fused group,

[0065] wherein the fused group is selected from: fused cycloalkyl, fused heterocycloalkyl, fused aryl and fused heteroaryl rings,

[0066] wherein the fused group contains 4 to 10 carbon atoms,

[0067] wherein n in formula III is 0 or 1,

[0068] wherein Q is a bond or O,

[0069] wherein X is C, N, O or S, and if X is O or S, then R 6 is absent, and

[0070] wherein Z 1 or W 1Independently C, N, O or S.

[0071] Another embodiment of the present invention includes a compound of formula III, wherein X is N.

[0072] One embodiment of the present invention includes a compound of formula III, wherein R 6 is hydrogen and X is N.

[0073] Another embodiment of the present invention includes a compound of formula III, wherein R 3 is alkyl and R 1 is cyano.

[0074] Another embodiment of the present invention includes a compound of formula III, wherein X is N and n = 0.

[0075] One embodiment of the present invention includes a compound of formula III, wherein X is N and n = 1.

[0076] Generally speaking, the present invention has successfully achieved the following benefits and objectives.

[0077] One objective of the present invention is to use a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt or ester thereof to treat diseases acting on fatty acid binding protein (FABP4).

[0078] One objective of the present invention is to provide a pharmaceutical composition comprising a compound of formula (I), (II) or (III) as an active ingredient and a pharmaceutically acceptable diluent or carrier for treating diseases acting on FABP4. Herein, the pharmaceutical composition may further comprise an additional therapeutic active agent.

[0079] One objective of the present invention is to provide a method for treating diseases acting on FABP4. This method includes multiple process steps, for example: administering an effective amount of a compound of formula (I), (II) or (III) to a subject (preferably a human) in need of such treatment. The method optionally includes process steps of co-administering with other therapeutic agents, or administering as a single (or multiple) dose, simultaneously or sequentially.

[0080] One objective of the present invention is to provide a method for inhibiting FABP4, including the process step of administering an effective amount of a compound of formula (I), (II) or (III) to a subject (preferably a human) in need of such treatment.

[0081] One object of the present invention is to provide a method for preparing a medicament for treating diseases acting on FABP4 using a compound of formula (I), (II) or (III). Examples of such diseases include type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer's disease, other chronic inflammatory and autoimmune / inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia and cancer.

[0082] Other features and advantages of the present invention will become apparent from the detailed description and the claims. Detailed Description

[0083] Reference will now be made in detail to various embodiments of the present invention. These embodiments are provided by way of explanation of the present invention, but the present invention is not limited thereto. In fact, those of ordinary skill in the art will understand that various modifications and variations can be made upon reading this specification and viewing the drawings.

[0084] Definitions

[0085] As used herein, the term "bioisostere" includes, but is not limited to, the following functional groups, where R is H or alkyl.

[0086]

[0087] The term "alkyl" refers to a saturated straight-chain or branched hydrocarbon group containing 1 to 20 carbon atoms. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, etc., as well as longer alkyls, such as heptyl, octyl, etc. In addition, the number of carbon atoms in the alkyl chain can be defined in combination with C atoms, such as C 1-10 where C 1-10 is a carbon chain containing 1 to 10 carbon atoms.

[0088] The term "alkoxy" as used herein refers to an alkyl group bonded to oxygen alone and includes -O-(alkyl), where alkyl is as defined above.

[0089] The term "amino" as used herein refers to the –NH 2 group.

[0090] The term "alkenyl" refers to a hydrocarbyl group formed when a hydrogen atom is removed from an alkene group. Alkenyl compounds are named by replacing the -ene in the name of the parent chain alkene with -yl. An example includes H2C=CH- (e.g., ethenyl or vinyl).

[0091] The term "alkynyl" refers to a moiety containing an open point of attachment on a carbon atom, which is formed if a hydrogen atom bonded to a triple-bonded carbon is removed from an alkyne molecule.

[0092] The term "haloalkyl" refers to any alkyl group in which one or more hydrogen atoms are replaced by halogen atoms.

[0093] The term "phenyl" refers to a monovalent hydrocarbyl group (C 6 H 5 ), formally derived from benzene by the removal of one hydrogen atom.

[0094] The term "naphthyl" refers to an isomeric monovalent radical formed by the removal of one hydrogen atom from naphthalene.

[0095] The term "pyrrole" refers to a heterocyclic aromatic organic compound, which is a five-membered ring having the chemical formula C 4 H 4 NH.

[0096] The term "imidazole" refers to an organic compound having the chemical formula C 3 N 2 H 4 .

[0097] The term "thiophene" refers to a heterocyclic compound having the molecular formula C 4 H 4 S.

[0098] The term "furan" refers to a heterocyclic organic compound consisting of a five-membered aromatic ring containing four carbon atoms and one oxygen.

[0099] The term "thiazole" refers to a heterocyclic compound containing sulfur and nitrogen and having the molecular formula C 3 H 3 NS.

[0100] The term "isothiazole" or 1,2-thiazole refers to an organic compound containing a five-membered aromatic ring composed of three carbon atoms, one nitrogen atom, and one sulfur atom.

[0101] The term "thiadiazole" refers to a subfamily of azole compounds, which are five-membered heterocyclic compounds containing one sulfur atom and two nitrogen atoms.

[0102] The term "oxazole" refers to the parent compound of a class of heterocyclic aromatic organic compounds. Oxazole is a type of azole in which oxygen and nitrogen are separated by one carbon atom.

[0103] The term "isoxazole" refers to an azole with an oxygen atom adjacent to the nitrogen atom.

[0104] The term "oxadiazole" refers to a class of heterocyclic aromatic compounds of the azole family with the molecular formula C 2 H 2 N 2 O.

[0105] The term "pyridine" refers to a basic heterocyclic organic compound with the chemical formula C 5 H 5 N. Pyridine is structurally related to benzene, where one methine group is replaced by a nitrogen atom.

[0106] The term "pyrazine" refers to a heterocyclic organic compound with the chemical formula C 4 H 4 N 2 . Pyrazine is less basic than pyridine, pyridazine, and pyrimidine.

[0107] The term "pyrimidine" refers to a heterocyclic organic compound similar to pyridine. Pyrimidine is one of three diazines, with nitrogen atoms at positions 1 and 3 of the ring.

[0108] The term "pyridazine" is a heterocyclic organic compound with the molecular formula (CH) 4 N 2 . Pyridazine contains a six-membered ring with two adjacent nitrogen atoms.

[0109] The term "pyrazole" refers to an organic compound with the molecular formula C 3 H 3 N 2 H. Pyrazole is a heterocycle characterized by a 5-membered ring containing three carbon atoms and two adjacent nitrogen atoms.

[0110] The term "triazole" refers to any heterocyclic compound with the molecular formula C 2 H 3 N 3 that has a five-membered ring containing two carbon atoms and three nitrogen atoms.

[0111] The term "tetrazole" refers to a class of synthetic organic heterocyclic compounds composed of a five-membered ring containing four nitrogen atoms and one carbon atom. The name tetrazole also refers to the parent compound with the molecular formula CH 2 N 4 .

[0112] The term "chroman" or "chromane" refers to a compound with the chemical formula C 9 H 10Heterocyclic compounds of O.

[0113] The term "quinoline" refers to a heterocyclic organic compound with the chemical formula C 9 H 7 N.

[0114] The term "quinoxaline" or "benzopyrazine" refers to a heterocyclic compound containing a ring complex composed of a benzene ring and a pyrazine ring.

[0115] The term "isoquinoline" refers to a heterocyclic aromatic organic compound. Isoquinoline is a structural isomer of quinoline. Isoquinoline and quinoline are benzopyridines, which are formed by the fusion of a benzene ring and a pyridine ring.

[0116] The terms "phthalazine", "benzo-orthodiazine" or "benzopyridazine" are heterocyclic organic compounds with the molecular formula C 8 H 6 N 2 It is isomeric with other naphthyridines, including quinoxaline, cinnoline and quinazoline.

[0117] The term "cinnoline" is a heterocyclic compound with the molecular formula C 8 H 6 N 2 It is isomeric with other naphthyridines, including quinoxaline, phthalazine and quinazoline.

[0118] The term "quinazoline" refers to an organic compound with the chemical formula C 8 H 6 N 2 Quinazoline is a heterocycle with a bicyclic structure, composed of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.

[0119] The term "indole" is a heterocyclic organic compound with the molecular formula C 8 H 7 N. Indole has a bicyclic structure, composed of a six-membered benzene ring fused to a five-membered pyrrole ring.

[0120] The term "isoindole" is a benzo-fused pyrrole and is an isomer of indole.

[0121] The term "indoline" is a heterocyclic organic compound with the chemical formula C 8 H 9 N. Indoline has a bicyclic structure, composed of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0122] The term "isoindoline" refers to a compound with the molecular formula C 8 H 9Heterocyclic organic compounds of N. The parent compound has a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0123] The term "benzothiophene" refers to an organic compound with the molecular formula C 8 H 6 S.

[0124] The term "benzofuran" refers to a heterocyclic compound consisting of a fused benzene ring and a furan ring.

[0125] The term "isobenzofuran" refers to a heterocyclic compound consisting of a fused benzene ring and a furan ring. Isobenzofuran is isomeric with benzofuran.

[0126] The term "benzoxazole" refers to an organic compound with the molecular formula C 7 H 5 NO, and includes a benzene-fused oxazole ring structure.

[0127] The term "benzothiazole" refers to a heterocyclic compound with the chemical formula C 7 H 5 NS.

[0128] The term "benzimidazole" refers to a heterocyclic organic compound. Benzimidazole is a bicyclic compound composed of a fusion of benzene and imidazole.

[0129] The term "indazole" or "isoindazole" refers to a heterocyclic organic compound composed of a fusion of benzene and pyrazole.

[0130] The term "benzodioxane" refers to isomeric compounds with the molecular formula C 8 H 8 O 2 .

[0131] The term "indane" or "indan" refers to an organic compound with the chemical formula C 6 H 4 (CH 2 ) 3 .

[0132] The term "acridine" refers to an organic compound and is a nitrogen heterocycle with the chemical formula C 13 H 9 N. Acridine is a substituted derivative of the parent ring. It is a planar molecule structurally related to anthracene, with a central CH group replaced by nitrogen.

[0133] The term "phenazine" refers to an organic compound with the chemical formula (C 6 H 4 ) 2 N 2 . Phenazine is a dibenzocyclopyrazine.

[0134] The term "xanthene" refers to an organic compound with the chemical formula CH 2 [C 6 H 4 2 O.

[0135] The term "isochroman" refers to a compound with the chemical formula C 9 H 10 O and having the following structure:

[0136]

[0137] The term "2,1,3-benzoxadiazole" refers to an organic compound having the following structure:

[0138]

[0139] The term "2,1,3-benzothiazole" refers to a heterocyclic compound with the chemical formula C 7 H 5 NS.

[0140] The term "2,1,3-benzoselenadiazole" refers to an organic compound having the following structure:

[0141]

[0142] The term "tetrahydroquinoline" refers to an organic compound that is a semi-hydrogenated derivative of quinoline.

[0143] The term "3,4-dihydro-2H-1,4-benzoxazine" refers to an organic compound having the following structure:

[0144]

[0145] The term "1,5-naphthyridine" refers to an organic compound having the following structure:

[0146]

[0147] The term "1,8-naphthyridine" refers to an organic compound with the chemical formula C 8 H 6 N 2 .

[0148] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic aromatic group, where all rings of the group are aromatic and all ring atoms are carbon atoms. For a bicyclic or tricyclic system, the individual aromatic rings are fused to each other. Examples of aryl groups are 6- and 10-membered aryls. Other examples of aryl groups include, but are not limited to, phenyl, naphthalene, and anthracene.

[0149] ​As used herein, the term "cyano" refers to a substituent containing a carbon atom linked to a nitrogen atom by a triple bond.

[0150] As used herein, the term "deuterium" refers to the stable isotope of hydrogen containing one proton and one neutron.

[0151] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, iodine, astatine or arsenic. The term "halo" represents a group containing a halogen.

[0152] The term "hydroxy" refers to the -OH group.

[0153] The term "oxo" refers to the =O group, which can be attached to a carbon atom or a sulfur atom.

[0154] The term "N-oxide" refers to the oxidized form of a nitrogen atom.

[0155] The term "cycloalkyl" refers to a saturated or partially saturated monocyclic, fused polycyclic, bridged polycyclic or spiro polycyclic carbocyclic ring containing 3 to 15 carbon ring atoms. A non-limiting class of cycloalkyl groups is a saturated or partially saturated monocyclic carbocyclic ring containing 3 to 6 carbon atoms. Illustrative examples of cycloalkyl include, but are not limited to, the following moieties:

[0156]

[0157]

[0158] As used herein, the term "heterocycloalkyl" refers to a saturated or partially saturated monocyclic or fused, bridged or spiro polycyclic structure containing 3 - 12 ring atoms selected from carbon atoms and up to 3 heteroatoms selected from nitrogen, oxygen and sulfur. The ring structure may optionally contain up to two oxo groups, or N-oxides, on a carbon or sulfur ring member. Illustrative heterocycloalkyl entities include, but are not limited to, the following:

[0159]

[0160] The term "heteroaryl" refers to a monocyclic or fused polycyclic, aromatic heterocycle containing 3 - 15 ring atoms selected from carbon, oxygen, nitrogen, and sulfur. Suitable heteroaryl groups do not include ring systems that must be charged to be aromatic, such as pyranylium. Suitable 5 - membered heteroaryl rings (either as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) contain one oxygen, sulfur, or nitrogen ring atom, or one nitrogen plus one oxygen or sulfur, or 2, 3, or 4 nitrogen ring atoms. Suitable 6 - membered heteroaryl rings (either as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) contain 1, 2, or 3 nitrogen ring atoms. Examples of heteroaryl include, but are not limited to, pyridyl, imidazolyl, imidazopyridyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuryl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiadiazole, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.

[0161] The term "fused heteroaryl" refers to a heteroaryl as defined above that contains two component aromatic rings, where the two rings are fused to each other and at least one ring is a heteroaryl as defined above. Fused heteroaryl includes fused heteroaryl containing 1, 2, 3, or 4 heteroatom ring atoms selected from O, N, or S. In certain embodiments, where the heteroatom is N, it can be an N - oxide. Fused heteroaryl also includes 8 - membered, 9 - membered, or 10 - membered fused heteroaryl. Fused heteroaryl also includes 8 - membered, 9 - membered, or 10 - membered fused heteroaryl containing 1, 2, 3, or 4 heteroatom ring atoms selected from O, N, or S. Illustrative examples of fused heteroaryl include, but are not limited to, the following:

[0162]

[0163] Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, and heterocycloalkyl listed or shown above are not exhaustive, and other species within the scope of these defined terms can also be selected.

[0164] As used herein, "liquid chromatography - mass spectrometry" or LC - MS is an analytical chemistry technique that combines the physical separation ability of liquid chromatography (or HPLC) with the mass analysis ability of mass spectrometry (MS).

[0165] As used herein, "proton nuclear magnetic resonance" or 1H NMR is the application of nuclear magnetic resonance in NMR spectroscopy, which involves hydrogen-1 nuclei in a molecular substance to determine its molecular structure.

[0166] As used herein, the term "substituted" means that a particular group or moiety bears one or more suitable substituents. As used herein, the term "unsubstituted" means that a particular group has no substituents. As used herein, the term "optionally substituted" means that a particular group is either unsubstituted or substituted with a specific number of substituents. When the term "substituted" is used to describe a structural system, substitution means occurring at any position allowed by the valence of the system.

[0167] The term "substituent" refers to an atom or group of atoms that replaces one or more hydrogen atoms on a hydrocarbon parent chain and becomes part of the resulting new molecule.

[0168] Any atom represented herein with an unsatisfied valence is considered to have a sufficient number of hydrogen atoms to satisfy the valence of that atom.

[0169] When any variable (e.g., alkyl, R a 、R 1 etc.) appears more than once in any chemical formula or description provided herein, the definition of that variable at each occurrence is independent of its definition at each other occurrence.

[0170] The numerical ranges used herein are intended to include consecutive integers. For example, a range expressed as "0 to 4" or "0-4" includes 0, 1, 2, 3, and 4.

[0171] When a polyfunctional moiety is shown, the point of attachment to the remainder of the molecular formula can be at any point on the polyfunctional moiety. In some embodiments, the point of attachment is represented by a line or a hyphen. For example, aryloxy- means a moiety in which the oxygen atom is the point of attachment to the core molecule and an aryl group is attached to the oxygen atom.

[0172] As used herein, the term "subject" includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the mammalian class, such as: humans, non-human primates (e.g., chimpanzees, apes, and monkeys), farm animals (e.g., cows, horses, sheep, goats, pigs, etc.), domestic animals (such as rabbits, dogs, cats, etc.), and laboratory animals (e.g., rodents, such as rats, mice, and guinea pigs, etc.). Examples of non-mammals include, but are not limited to, birds, fish, etc. In one embodiment of the present invention, the mammal is a human.

[0173] The term "patient" or "subject" includes humans and animals.

[0174] The term "effective amount" or "therapeutically effective amount" means an amount of an agent sufficient to provide the desired biological result. This result can be alleviation and / or reduction of the signs, symptoms, or causes of a disease or medical condition, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a compound or a composition containing the compound required to provide a clinically relevant change in a disease state, symptom, or medical condition. A person of ordinary skill in the art can use routine experimentation to determine the appropriate "effective" amount in any individual case. Thus, the term "effective amount" generally refers to the amount at which an active substance has the desired therapeutic effect.

[0175] As used herein, the terms "treat" or "treatment" include "prophylactic" and "curative" treatment. As used herein, the phrase "prophylactic treatment" means delaying the development of a disease, disease symptom, or medical condition, suppressing symptoms that may occur, or reducing the risk of development or recurrence of a disease or symptom. As used herein, the phrase "curative treatment" means reducing the severity of an existing disease, symptom, or condition or suppressing its worsening. Thus, "treatment" includes ameliorating or preventing the worsening of existing disease symptoms, preventing the occurrence of additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, suppressing a disorder or disease, e.g., preventing the development of a disorder or disease, alleviating a disorder or disease, causing the regression of a disorder or disease, alleviating the symptoms caused by a disease or disorder, or stopping the symptoms of a disease or disorder.

[0176] Specific embodiments

[0177] Formula I

[0178] In one embodiment, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof:

[0179]

[0180] wherein R 1 and R 6 -R 9 are each independently -H, -CN, -COOH, -CONH 2 , B(ORa) 2 , an acid isostere, a halogen, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0181] wherein B(ORa ) 2 The R in a is H or an alkyl group,

[0182] wherein B(OR a ) 2 the B in is boron,

[0183] wherein n in C n is from 1 to 10,

[0184] wherein R 2 -R 5 are each independently -H, -CN, -COOH, -COOMe, -CONH 2 , B(OR a ) 2 , an acid bioisostere, a halogen, -CONHOH, -NH-SO 2 -Cι-C 6 -alkyl, -NHSO 2 Ar, C n alkyl, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl,

[0185] wherein -NHSO 2 Ar, Ar is selected from: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4,-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene,

[0186] wherein C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C nHaloalkyl, C n Heteroaryl, C n Cycloalkyl and C n Heterocycloalkyl is unsubstituted or substituted by 1-5 substituents,

[0187] Wherein the substituents are the same or different,

[0188] Wherein each substituent is selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl and -C q -UC q ,

[0189] Where -C q -UC q Each q in is independently 0 to 10,

[0190] Where -C q -UC q U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ) in any one of the following:

[0191] Where N(R 1 )(R 1 ) in each R 1 Independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl,

[0192] Where N(R 1 )(R 1 ) in each R 1 is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents, which may be the same or different and are independently selected from: H, 2 ​​​​​​​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl,

[0193] wherein Q is a bond or O,

[0194] wherein X is C, N, O or S, and if X is O or S, then R is absent 6 ,

[0195] wherein “A” is a saturated or unsaturated ring represented by and

[0196] wherein Y, T, W and Z are independently a bond, C, N, O, an alkyl having 1 to 4 carbon atoms or an alkenyl having 1 to 4 carbon atoms, and

[0197] wherein n is 0, 1, 2 or 3.

[0198] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 1 and R 2 is bonded to form a fused heteroaryl.

[0199] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 2 and R 3 is bonded to form a fused heteroaryl.

[0200] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 3 and R 4 is bonded to form a fused heteroaryl.

[0201] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 4 and R 5 is bonded to form a fused heteroaryl.

[0202] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 5 and R 6 is bonded to form a fused heteroaryl.

[0203] In one embodiment, the present invention includes a compound of formula I, wherein at least one of R 6 and R 7At least one of them bonds to form a fused heteroaryl.

[0204] In one embodiment, the present invention includes a compound of formula I, wherein R 7 and R 8 At least one of them bonds to form a fused heteroaryl.

[0205] In one embodiment, the present invention includes a compound of formula I, wherein R 8 and R 9 At least one of them bonds to form a fused heteroaryl.

[0206] In one embodiment, the present invention includes a compound of formula I, wherein R 1 and R 2 At least one of them bonds to form a fused heterocycloalkyl.

[0207] In one embodiment, the present invention includes a compound of formula I, wherein R 2 and R 3 At least one of them bonds to form a fused heterocycloalkyl.

[0208] In one embodiment, the present invention includes a compound of formula I, wherein R 3 and R 4 At least one of them bonds to form a fused heterocycloalkyl.

[0209] In one embodiment, the present invention includes a compound of formula I, wherein R 4 and R 5 At least one of them bonds to form a fused heterocycloalkyl.

[0210] In one embodiment, the present invention includes a compound of formula I, wherein R 5 and R 6 At least one of them bonds to form a fused heterocycloalkyl.

[0211] In one embodiment, the present invention includes a compound of formula I, wherein R 6 and R 7 At least one of them bonds to form a fused heterocycloalkyl.

[0212] In one embodiment, the present invention includes a compound of formula I, wherein R 7 and R 8 At least one of them bonds to form a fused heterocycloalkyl.

[0213] In one embodiment, the present invention includes a compound of formula I, wherein R 8 and R 9 At least one of them bonds to form a fused heterocycloalkyl.

[0214] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 1 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0215] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is -H, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0216] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is -CN, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0217] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is -COOH, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0218] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is -CONH 2 , and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0219] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is B(OR a ) 2 , wherein B(OR a ) 2in which B is boron, where B(OR a ) 2 in which R a is H, and where R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0220] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, in which each moiety is independently selected, where R 1 and R 6 -R 9 in which at least one of B(OR a ) 2 , where B(OR a ) 2 in which B is boron, where B(OR a ) 2 in which R a is alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0221] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, in which each moiety is independently selected, where R 1 and R 6 -R 9 in which at least one is an acid isostere as disclosed herein, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0222] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, in which each moiety is independently selected, where R 1 and R 6 -R 9 in which at least one is a halogen, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0223] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, in which each moiety is independently selected, where R 1 and R 6 -R 9 in which at least one is C n alkyl, where n in C n alkyl is 1 - 10, where C n alkyl is unsubstituted, and where R 2 -R 5, W, T, Y, Z, Q, and X are as defined.

[0224] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is C n alkyl, wherein n in C n alkyl is 1 - 10, wherein C n alkyl is substituted with 1 substituent, wherein the substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0225] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is C n alkyl, wherein n in C n alkyl is 1 - 10, wherein C n alkyl is substituted with 2 - 5 substituents, wherein the substituents are the same, and wherein each of the substituents is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0226] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R6 -R 9 At least one of them is C n alkyl, where C n In the alkyl, n is 1 - 10, where C n The alkyl is substituted by 2 - 5 substituents, where these substituents are different, and where each of these substituents is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0227] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 At least one of them is a substituted C n alkyl, where C n In the alkyl, n is 1 - 10, where the number of substituents is 1, where the substituent is H, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0228] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 At least one of them is a substituted C n alkyl, where C n in which n is 1 - 10, where the number of substituents is 1, where the substituent is 2 H, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0229] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 At least one of them is a substituted C n alkyl, where Cn wherein n in is from 1 to 10, the number of substituents is 1, the substituent is a halogen, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0230] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, the number of substituents is 1, the substituent is an amino group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0231] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, the number of substituents is 1, the substituent is an alkoxy group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0232] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, the number of substituents is 1, the substituent is a cyano group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0233] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein C nwhere n in is 1 - 10, where the number of substituents is 1, where the substituent is aminoalkyl-, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0234] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is (amino)alkoxy-, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0235] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is -alkyl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0236] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is -alkenyl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0237] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C nwherein n in is from 1 to 10, wherein the number of substituents is 1, wherein the substituent is an -alkynyl group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0238] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, wherein the number of substituents is 1, wherein the substituent is an alkoxy-group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0239] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, wherein the number of substituents is 1, wherein the substituent is a hydroxyl group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0240] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is from 1 to 10, wherein the number of substituents is 1, wherein the substituent is an -alkylhydroxyl group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0241] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C nwherein n in is 1 - 10, the number of substituents is 1, the substituent is an aryloxy - group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0242] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, the substituent is an - alkyl(aryl) group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0243] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, the substituent is an (alkoxyalkyl)amino - group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0244] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, the substituent is an aryl group, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0245] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein C nwhere n in is 1 - 10, where the number of substituents is 1, where the substituent is a -aryl(halo) group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0246] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is a -heteroaryl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0247] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is a hydroxy - alkyl - group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0248] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is a hydroxy - aryl - group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0249] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C nwhere n in is 1 - 10, where the number of substituents is 1, where the substituent is an (aryl)alkyl-group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0250] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is -S(O) 2 -alkyl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0251] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is -S(O) 2 -aryl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0252] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, where the substituent is -C(O)alkyl group, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0253] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where Cn where n is from 1 to 10, the number of substituents is 1, and the substituent is -C q -U-C q where -C q -U-C q each q in is independently from 0 to 10, where -C q -U-C q U in is an aryl, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0254] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, where n in C n is from 1 to 10, the number of substituents is 1, and the substituent is -C q -U-C q where -C q -U-C q each q in is independently from 0 to 10, where -C q -U-C q U in is a heteroaryl, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0255] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, where n in C n is from 1 to 10, the number of substituents is 1, and the substituent is -C q -U-C q where -C q -U-C q each q in is independently from 0 to 10, where -C q -U-C q U in is a cycloalkyl, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0256] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where R1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, and the substituent is -C q -U-C q , wherein -C q -U-C q each q in which is independently 0 - 10, wherein -C q -U-C q U in which is a heterocycloalkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0257] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, and wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, and the substituent is -C q -U-C q , wherein -C q -U-C q each q of which is independently 0 - 10, wherein -C q -U-C q U in which is O, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0258] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, and wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, and the substituent is -C q -U-C q , wherein -C q -U-C q each q of which is independently 0 - 10, wherein -C q -U-C q U in which is S, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0259] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, wherein n in C n is 1-10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is SO 2 , and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0260] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, wherein n in C n is 1-10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0261] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, wherein n in C n is 1-10, wherein the number of substituents is 1, and wherein the substituent is -Cq -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q wherein U in is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently C 1 alkyl, and wherein R n -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0262] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q wherein U in is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently C 1 alkenyl, and wherein R n -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0263] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein -C q -U-C qeach q in is independently 0 - 10, where -C q -U-C q U in is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently C 1 alkynyl, and where R n –R 2 –R 5 、W、T、Y、Z、Q and X are as defined.

[0264] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 –R 9 is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, and the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where -C q -U-C q U in is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently C 1 aryl, and where R n –R 2 –R 5 、W、T、Y、Z、Q and X are as defined.

[0265] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 –R 9 is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, and the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where -C q -U-C q U in is N(R 1 )(R 1), wherein each R in N(R 1 )(R 1 ) is independently C 1 aminoalkyl, and wherein R n -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0266] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is a substituted C n alkyl, wherein n in C n is 1-10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently C 1 haloalkyl, and wherein R n -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0267] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is a substituted C n alkyl, wherein n in C n is 1-10, wherein the number of substituents is 1, and wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently C 1 haloalkyl, and wherein R na heteroaryl, and wherein R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0268] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, wherein the number of substituents is 1, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently C n cycloalkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0269] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, wherein the number of substituents is 1, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently C n heterocycloalkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0270] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, and the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is unsubstituted, and R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0271] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in C n is 1 - 10, where the number of substituents is 1, and the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, Cn Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R 1 )(R 1 ) in each R 1 is substituted by a substituent, wherein the substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, aryl(halogenated), heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0272] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of them is substituted C n Alkyl, where C n wherein n is 1-10, wherein the number of substituents is 1, wherein the substituent is -C q -UC q , where -C q -UC q Each q in is independently 0-10, wherein -C q -UC q U is N(R 1 )(R 1 ), where N(R 1 )(R 1 ) in each R 1 Independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R 1 )(R 1 ) in each R 1 Substituted by 2-5 substituents, each of which is the same, each of which is H, 2 ​​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0273] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n is 1 - 10, wherein the number of substituents is 1, and the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R 1 in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, wherein each substituent is different, and each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, aryl-, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 –R 5, W, T, Y, Z, Q, and X are as defined.

[0274] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n is 1-10, where the number of substituents is 2-5, where each substituent is the same, where each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0275] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n is 1-10, where the number of substituents is 2-5, where each substituent is different, where each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0276] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C nAn alkyl group, where n is from 1 to 10, where the number of substituents is from 2 to 5, where each substituent is the same, and each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0277] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where R 1 and R 6 -R 9 in at least one is a substituted C n alkyl group, where n is from 1 to 10, where the number of substituents is from 2 to 5, where each substituent is different, and each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0278] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where R 1 and R 6 -R 9 in at least one is a substituted C n alkyl group, where n is from 1 to 10, where the number of substituents is from 2 to 5, and where at least one of these substituents is -C q -U-C q , where -C q -U-Cq Each q in is independently 0 - 10, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0279] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of is a substituted C n alkyl, wherein n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q wherein -C q -U-C q Each q in is independently 0 - 10, wherein -C q -U-C q U in is aryl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0280] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of is a substituted C n alkyl, wherein n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q wherein -C q -U-C q Each q in is independently 0 - 10, wherein -C q -U-C q U in is heteroaryl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0281] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of is a substituted C n alkyl, wherein n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q wherein -Cq -U-C q each q in -C q -U-C q is independently 0 - 10, where -C 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0282] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n is 1 - 10, where the number of substituents is 2 - 5, where at least one of these substituents is -C q -U-C q where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is a heterocycloalkyl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0283] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, where n is 1 - 10, where the number of substituents is 2 - 5, where at least one of these substituents is -C q -U-C q where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is O, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0284] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C nAn alkyl group, where n is 1 - 10, where the number of substituents is 2 - 5, and where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q in U is S, and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0285] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, and where R 1 and R 6 -R 9 at least one of is a substituted C n alkyl group, where n is 1 - 10, where the number of substituents is 2 - 5, and where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q in U is SO 2 , and where R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0286] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, and where R 1 and R 6 -R 9 at least one of is a substituted C n alkyl group, where n is 1 - 10, where the number of substituents is 2 - 5, and where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q in U is N(R 1 )(R 1 ), where each R 1 )(R 1 ) in N(R 1 is independently hydrogen, C n alkyl, C n alkenyl, Cn an alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0287] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0288] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein N(R1 )(R 1 ) each R in 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, N(R 1 )(R 1 ) each R in 1 is substituted with 1 - 5 substituents, where each substituent is the same, and each substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0289] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where at least one of R 1 and R 6 -R 9 is a substituted C n alkyl, where n is 1 - 10, where the number of substituents is 2 - 5, and where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and where U in -C q -U-C q is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R in N(R 1 )(R 1 ) is substituted with 1 - 5 substituents, where each substituent is different, and each substituent is H, 1 2 ​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0290] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein n in C n is 1-10, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0291] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein n in C n is 1-10, wherein C n alkenyl is unsubstituted, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0292] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0293] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein C n in which n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0294] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein Cn where n is from 1 to 10 in which C n alkenyl is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q where each q is independently from 0 to 10 in which -C q -U-C q where U in -U-C- is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with one substituent, which includes: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0295] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 1 and R 6 -R 9 is C n alkenyl, where n is from 1 to 10 in C n alkenyl is substituted with one substituent, where the substituent is -C n -U-C q , where -C q -U-C q where each q is independently from 0 to 10 in -C q -U-C q -U-C qU in the following is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ) where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is substituted with 2 - 5 substituents, these substituents being the same and including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0296] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 1 and R 6 -R 9 is C n alkenyl, where n in C n is 1 - 10, where C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, Cn Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, these substituents being different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroalkyl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0297] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n alkenyl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0298] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n alkenyl, wherein n in C n is 1 - 10, wherein the C nThe alkenyl is substituted with 2 to 5 substituents, where these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0299] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 in at least one is C n alkenyl, where n in C n is 1 - 10, where the C n alkenyl is substituted with 2 to 5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is unsubstituted, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0300] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R6 -R 9 at least one of which is C n alkenyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 1 substituent, and this substituent includes: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0301] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkenyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -Cq -U-C q Each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 2 - 5 identical substituents, and these substituents include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0302] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is C n alkenyl, where n in C n is 1 - 10, where C n alkenyl is substituted with 2 - 5 substituents, where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 2-5 substituents, which are different and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0303] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n aryl, wherein n in C n is 1-10, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0304] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n aryl, wherein n in C n is 1-10, wherein C n alkenyl is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0305] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R6 -R 9 At least one of them is C n aryl, wherein C n in which n is 1-10, wherein C n the alkenyl is substituted with 1 substituent, wherein the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0306] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of them is C n aryl, wherein C n in which n is 1-10, wherein C n the alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein -C q -U-C q in which each q is independently 0-10, wherein -C q -U-C q in which U is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0307] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 substituent, the substituent including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0308] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein n in C n is 1-10, wherein C nThe alkenyl is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 ) is substituted with 2 - 5 substituents, these substituents being the same and including: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0309] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 1 and R 6 -R 9 is C n aryl, where n in C n is 1 - 10, where the alkenyl in C n is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2 and N(R 1 )(R 1 ), where N(R 1 )(R 1 ) in each R 1 Independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R 1 )(R 1 ) in each R 1 Substituted with 2-5 substituents which vary and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0310] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of is C n Aryl, wherein C n n is 1-10, where C n Alkenyl is substituted with 2-5 substituents, wherein these substituents are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0311] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0312] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R1 is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0313] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with one substituent, which substituent includes: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0314] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R6 -R 9 at least one of which is C n aryl, wherein C n in which n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q in which each q is independently 0-10, wherein -C q -U-C q in which U is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 2-5 substituents, these substituents being the same and including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0315] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aryl, wherein C n in which n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q, wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 2 - 5 substituents, these substituents being different and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0316] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein R 1 and R 6 -R 9 at least one of them is C n aminoaryl, wherein n in C n is 1 - 10, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0317] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein R 1 and R 6 -R 9 at least one of them is C n aminoaryl, wherein n in C n is 1 - 10, wherein Cn The alkenyl is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0318] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a C n aminoaryl, wherein n in C n is 1 - 10, wherein the alkenyl in C n is substituted with 1 substituent, and the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0319] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a C n aminoaryl, wherein n in C n is 1 - 10, wherein the alkenyl in C n is substituted with 1 substituent, and the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, Cn An alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is unsubstituted, and wherein R 1 –R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0320] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 –R 9 is a C n aminoaryl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, and the substituent is -C q –U–C q , wherein each q in -C q –U–C q is independently 0-10, and U in -C q –U–C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 ) is substituted with 1 substituent, and the substituent includes: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl–, (amino)alkoxy–, –alkyl, –alkenyl, –alkynyl, alkoxy–, hydroxy, –alkylhydroxy, aryloxy–, –alkyl(aryl), (alkoxyalkyl)amino–, –aryl, –aryl(halo), –heteroaryl, hydroxy–alkyl–, hydroxy–aryl–, (aryl)alkyl–, –S(O) 1 –alkyl, –S(O) 2 –aryl or –C(O)alkyl, and wherein R 2 –R 2 –R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0321] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 2-5 substituents, which are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0322] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1-10, wherein Cn The alkenyl is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 2 - 5 substituents, which are different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0323] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 1 and R 6 -R 9 is C n aminoaryl, where n in C n is 1 - 10, where the alkenyl in C n is substituted with 2 - 5 substituents, where these substituents are the same and include: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W, T, Y, Z, Q and X are as defined.

[0324] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W, T, Y, Z, Q and X are as defined.

[0325] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein C n in which n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C qU in the following is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is unsubstituted, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0326] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where at least one of R 1 and R 6 -R 9 is C n aminoaryl, where n in C n is 1-10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0-10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is substituted with 1 substituent, and the substituent includes: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0327] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 2-5 substituents, these substituents being the same and including: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -alkyl, -S(O)2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0328] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, these substituents being different and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q, and X are as defined.

[0329] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein C n in which n is 1 - 10, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0330] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein C n in which n is 1 - 10, wherein C n alkenyl is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0331] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein C n in which n is 1 - 10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0332] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein C n in which n is 1 - 10, wherein Cn The alkenyl group is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q each q of is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is unsubstituted, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0333] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where at least one of R 1 and R 6 -R 9 is C n haloalkyl, where n in C n is 1 - 10, where the alkenyl group is substituted with one substituent, where the substituent is -C n -U-C q , where -C q -U-C q each q of is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO q and N(R 2 )(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R1 )(R 1 ) each R in 1 is substituted by one substituent, which substituent includes: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0334] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein n in C n is 1 - 10, wherein the alkenyl is substituted by one substituent, which substituent is -C n -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO q and N(R 2 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C 1 alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R n ) is substituted by 2 - 5 substituents, which substituents are the same and include: H, 1 )(R 1 ) each R in 1 is independently hydrogen, C 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0335] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 2 - 5 substituents, these substituents being different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2-aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0336] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0337] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n haloalkyl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0338] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is C n haloalkyl, where n in C n is 1 - 10, where C n alkenyl is substituted with 2 - 5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is unsubstituted, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0339] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is C n haloalkyl, where n in C n is 1 - 10, where C n alkenyl is substituted with 2 - 5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R1 )(R 1 ),wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with one substituent, and the substituent includes: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0340] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 1 and R 6 -R 9 is C n haloalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, and at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C nAn alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is substituted with 2 to 5 substituents, which are the same and include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0341] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is a C n haloalkyl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 to 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 2 to 5 substituents, which are different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W, T, Y, Z, Q and X are as defined.

[0342] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heteroalkyl, wherein n in C n is 1-10, and wherein R 2 -R 5 、W, T, Y, Z, Q and X are as defined.

[0343] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1-10, wherein C n alkenyl is unsubstituted, and wherein R 2 -R 5 、W, T, Y, Z, Q and X are as defined.

[0344] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heteroalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0345] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heteroalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q U is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0346] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heteroalkyl, wherein Cn where n in is 1 - 10, and C n alkenyl is substituted with one substituent, and the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R in N(R n )(R 1 ) is substituted with one substituent, and the substituent includes: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0347] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and at least one of R 1 and R 6 -R 9 is C n heteroalkyl, where n in C n is 1 - 10, and C n alkenyl is substituted with one substituent, and the substituent is -C q -U-C q , where -C q -U-C q each q of is independently 0 - 10, where -C q -U-C qU in the following is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 2 - 5 substituents, these substituents being the same and including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0348] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n heteroalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 1 substituent, and wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, Cn alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, which are different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0349] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n heteroalkyl, wherein n in C n is 1 - 10, wherein the C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0350] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n heteroalkyl, wherein n in C n is 1 - 10, wherein C nThe alkenyl is substituted with 2 to 5 substituents, where these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0351] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R 6 -R 9 At least one of which is C n heteroalkyl, where n in C n is 1 - 10, where the alkenyl in C n is substituted with 2 to 5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is unsubstituted, and where R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0352] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where R 1 and R6 -R 9 at least one of which is C n heteroalkyl, wherein C n in which n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q in which each q is independently 0 - 10, wherein -C q -U-C q in which U is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 1 substituent, which substituent includes: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0353] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heteroalkyl, wherein C n in which n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -Cq -U-C q each q in -C q -U-C q is independently 0 - 10, where -C 2 -U-C 1 U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 1 and N(R 1 )(R 1 ), where each R in N(R 1 )(R n is independently hydrogen, C n alkyl, C n alkenyl, C 1 alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, these substituents being the same and including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0354] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of is C n heteroalkyl, where n in C n is 1 - 10, where C n alkenyl is substituted with 2 - 5 substituents, where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1), wherein N(R 1 )(R 1 ) each R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 )(R 1 ) is substituted with 2-5 substituents, and these substituents are different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo)-, -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0355] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0356] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n aminoaryl, wherein n in C n is 1-10, wherein C n alkenyl is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0357] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, wherein the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0358] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is unsubstituted, and wherein R 1 –R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0359] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 substituent, the substituent including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0360] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, wherein C nThe alkenyl is substituted with one substituent, where the substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R in N(R n )(R 1 ) is substituted with 2 - 5 substituents, which are the same and include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, where R 2 -R 2 、W、T、Y、Z、Q and X are as defined.

[0361] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, and at least one of R 2 and R 5 -R 1 is C 6 cycloalkyl, where n in C 9 is 1 - 10, and the alkenyl is substituted with one substituent, where the substituent is -C n -U-C n , where each q in -C n -U-C q is independently 0 - 10, and U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO q and N(R q -U-C q ​2 and N(R 1 )(R 1 ), where N(R 1 )(R 1 ) in each R 1 Independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R 1 )(R 1 ) in each R 1 Substituted with 2-5 substituents which vary and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0362] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of is C n Cycloalkyl, where C n n is 1-10, where C n Alkenyl is substituted with 2-5 substituents, wherein these substituents are the same and include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0363] ​​​​​​One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0364] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R1 is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0365] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 )(R 1 ) in N(R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 )(R 1 ) in N(R 1 is substituted with 1 substituent, which substituent includes: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0366] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R6 -R 9 at least one of which is C n cycloalkyl, where n in C n is 1-10, where C n alkenyl is substituted with 2-5 substituents, where at least one of these substituents is -C q -U-C q , where -C q -U-C q each q in is independently 0-10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 2-5 substituents, these substituents are the same and include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, where R 2 -R 2 , W, T, Y, Z, Q and X are as defined. 5

[0367] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, where n in C n is 1-10, where C n alkenyl is substituted with 2-5 substituents, where at least one of these substituents is -C q -U-C q, where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is substituted with 2 - 5 substituents, which are different and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0368] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, where n in C n is 1 - 10, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0369] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where R 1 and R 6 -R 9 at least one of which is C n aminoaryl, where n in C n is 1 - 10, where Cn The alkenyl is unsubstituted, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0370] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, and the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0371] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, and the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, Cn An alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is unsubstituted, and wherein R 1 –R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0372] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 ) is substituted with 1 substituent, the substituent including: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 –R 2 –R 2 –R 5 , W, T, Y, Z, Q and X are as defined.

[0373] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 1 substituent, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 2-5 substituents, these substituents being the same and including: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0374] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein Cn The alkenyl is substituted with one substituent, where the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 2 - 5 substituents, which are different and may include: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 2 -R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0375] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 1 and R 6 -R 9 is C n heterocycloalkyl, where n in C n is 1 - 10, where the alkenyl is substituted with 2 - 5 substituents, where these substituents are the same and include: H, n 2 ​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0376] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein the moieties are independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein these substituents are different and independently are: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 、W、T、Y、Z、Q and X are as defined.

[0377] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein the moieties are independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C qU in the following is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is unsubstituted, and where R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0378] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where at least one of R 1 and R 6 -R 9 is C n heterocycloalkyl, where n in C n is 1-10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of these substituents is -C q -U-C q , where each q in -C q -U-C q is independently 0-10, where U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R 1 )(R 1 ) 1 is substituted with 1 substituent, which includes: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0379] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n heterocycloalkyl, wherein n in C n is 1-10, wherein the C n alkenyl is substituted with 2-5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0-10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 2-5 substituents, these substituents being the same and comprising: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O)2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0380] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n cycloalkyl, wherein n in C n is 1 - 10, wherein C n alkenyl is substituted with 2 - 5 substituents, wherein at least one of these substituents is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein -C q -U-C q U in is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 and N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 2 - 5 substituents, these substituents being different and may include: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0381] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, R2 -R 5 each independently is -H, -CN, -COOH, -COOMe, -CONH 2 , B(OR a ) 2 , an acid bioisostere, a halogen, -CONHOH, -NH-SO 2 -Cι-C 6 -alkyl, -NHSO 2 Ar, C n alkyl, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein B in B(OR a ) 2 is boron, and R in B(OR a ) 2 is H or alkyl, and wherein R a , R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0382] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 2 -R 5 is -NHSO 2 Ar, wherein Ar in -NHSO 2 Ar is selected from: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiadiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0383] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is naphthyl, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0384] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is pyrrole, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0385] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is imidazole, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0386] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is thiophene, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0387] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is isothiazole, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0388] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is thiadiazole, and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0389] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is oxazole, and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0390] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoxazole, and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0391] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is oxadiazole, and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0392] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyridine, and wherein R 1 、R 6 -R 9, W, T, Y, Z, Q, and X are as defined.

[0393] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrazine, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0394] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrimidine, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0395] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyridazine, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0396] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrazole, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0397] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is triazole, and wherein R 1 , R 6 -R9 , W, T, Y, Z, Q, and X are as defined.

[0398] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is tetrazole, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0399] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is chroman, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0400] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isochroman, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0401] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinoline, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0402] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinoxaline, and wherein R 1 , R6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0403] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoquinoline, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0404] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is phthalazine, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0405] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is cinnoline, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0406] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinazoline, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0407] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indole, and wherein R1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0408] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoindole, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0409] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indoline, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0410] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoindoline, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0411] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzothiophene, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0412] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2Ar, where Ar is benzofuran, and where R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0413] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isobenzofuran, and where R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0414] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzoxazole, and where R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0415] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzoxadiazole, and where R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0416] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzothiazole, and where R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0417] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzothiazole, and where R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0418] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzoselenadiazole, and where R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0419] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzimidazole, and where R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0420] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indazole, and where R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0421] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzodioxane, and where R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0422] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indane, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0423] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0424] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 3,4-dihydro-2H-1,4-benzoxazine, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0425] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,5-naphthyridine, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0426] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,8-naphthyridine, and wherein R 1 、R 6 -R 9, W, T, Y, Z, Q, and X are as defined.

[0427] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is acridine, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0428] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is phenazine, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0429] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is xanthene, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0430] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is unsubstituted C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl, where n in C n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0431] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in which at least one is C substituted with 1 substituent n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein C n in which n is 1 - 10, wherein the substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2- alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0432] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in which at least one is C substituted with 1 substituent n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein C n in which n is 1 - 10, wherein the substituent is -C q -U-C q wherein each q in -C q -U-C q is independently 0 - 10, wherein U in -C q -U-C q is one of the following: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2and N(R 1 )(R 1 ), and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0433] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein n in C n is 1-10, wherein the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0434] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, Cn haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein n in C n is from 1 to 10, wherein the substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently from 0 to 10, wherein -C q -U-C q in U is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 1 to 5 identical substituents, wherein these substituents are H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 2 -R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0435] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein at least one of R 2 -R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl or C n heterocycloalkyl, wherein n in C nwhere n is from 1 to 10, and the substituent is -C q -U-C q where -C q -U-C q each q in is independently from 0 to 10, where -C q -U-C q U in is N(R 1 )(R 1 ) where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 1 to 5 different substituents, where the 1 to 5 substituents are each H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and where R 2 -R 1 -R 6 -R 9 -R

[0436] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, where at least one of R 2 -R 5 is a substituted C n alkyl, where the number of substituents is 1, and the substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, where n in C n is from 1 to 10, and where R1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0437] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkyl, wherein the number of substituents is 2 - 5, wherein each substituent is the same and is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, wherein n in C n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0438] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkyl, wherein the number of substituents is 2 - 5, wherein each substituent is different and is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, wherein n in C n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0439] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2-R 5 at least one of which is a substituted C n alkyl group, where the number of substituents is 1, and the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where n in C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0440] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, and where at least one of R 2 -R 5 is a substituted C n alkyl group, where the number of substituents is 1, and the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where U is N(R 1 )(R 1 ), and where each R 1 in N(R 1 )(R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where n in C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0441] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, and where at least one of R 2 -R 5 is a substituted C n alkyl group, where n in C n is 1 - 10, where the number of substituents is 1, and the substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where U is N(R 1 )(R1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is unsubstituted, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0442] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 2 -R 5 is a substituted C n alkyl, wherein n in C n is 1 - 10, the number of substituents is 1, and the substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, and U is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) 1 is substituted with 1 - 5 substituents, wherein the 1 - 5 substituents are the same or different and are independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0443] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is an unsubstituted C n alkenyl, wherein n in C n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0444] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a C n alkenyl substituted with 1 - 5 substituents, wherein n in C n is 1 - 10, wherein each of these substituents is the same or different and includes H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q, and X are as defined.

[0445] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkenyl, wherein n in C n is 1 - 10, wherein the number of substituents is 2 - 5, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U is N(R 1 )(R 1 ), wherein N(R1 )(R 1 ) each R in 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is 1 substituted with 1-5 substituents, wherein each R in N(R 1 )(R 1 ) is 1 the same or different and is independently selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0446] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n alkynyl, wherein n in C n is 1-10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0447] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is unsubstituted C n alkynyl, wherein n in C n is 1-10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0448] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a C n alkynyl group substituted with 1 to 5 identical or different substituents, wherein n in C n is 1 to 10, wherein the said / some substituents are H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0449] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkynyl group, wherein n in C n is 1 to 10, wherein the number of substituents is 1 to 5, wherein the said / some substituents are -C q -U-C q , wherein each q in -C q -U-C q is independently 0 to 10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 to 5 substituents, wherein each R 1 in N(R 1 )(R 1 ) is the same or different and is independently selected from H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0450] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n aryl, wherein n in C n is 1 - 10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0451] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is an unsubstituted C n aryl, wherein n in C n is 1 - 10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0452] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a substituted C n aryl, wherein n in C n is 1 - 10, wherein the number of substituents is 1 - 5, wherein the substituents are the same or different, and wherein each substituent among the substituent(s) is: H, 2H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q , and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0453] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a substituted C n aryl, wherein n in C n is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 ) is substituted with 1-5 substituents, wherein each R in N(R 1 )(R 1 ) has substituents that are the same or different and are independently selected from H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 1 -aryl and -C(O)alkyl, and wherein R 2 、R 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 、R6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0454] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C n aminoalkyl, wherein n in C n is 1-10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0455] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is unsubstituted C n aminoalkyl, wherein n in C n is 1-10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0456] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C n aminoalkyl substituted with 1-5 substituents, wherein n in C n is 1-10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q , and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q, and X are as defined.

[0457] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n aminoalkyl, wherein n in C n is 1-10, wherein the number of substituents is 1-5, and wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and each R in N(R 1 )(R 1 ) 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R in N(R 1 )(R 1 ) 1 is substituted with 1-5 substituents, and the substituents of each R in N(R 1 )(R 1 ) 1 are the same or different and are independently selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0458] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C n haloalkyl, wherein n in C n is 1-10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0459] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is an unsubstituted C n haloalkyl, wherein the n in C n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0460] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a C n haloalkyl substituted with 1 - 5 substituents, wherein the n in C n is 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C q -U-C q or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0461] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n haloalkyl, wherein the n in C n is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C nAlkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is substituted with 1 - 5 substituents, and wherein each R in N(R 1 )(R 1 ) has the same or different substituents and is independently selected from H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 2 , R 2 -R 1 , W, T, Y, Z, Q and X are as defined.

[0462] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 6 -R 9 is a C 2 heteroaryl, wherein n in C 5 is 1 - 10, and wherein R n , R n -R 1 , W, T, Y, Z, Q and X are as defined.

[0463] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 6 -R 9 is an unsubstituted C 2 heteroaryl, wherein n in C 5 is 1 - 10, and wherein R n , R n -R 1 , W, T, Y, Z, Q and X are as defined.

[0464] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 9 -R 2 is a C 5 substituted with 1 - 5 substituents n n ​Heteroaryl, wherein C n in n has n of 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0465] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein at least one of R 2 -R 5 is a substituted C n heteroaryl, wherein C n in n has n of 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is -C q -U-C q wherein each q in -C q -U-C q is independently 0 - 10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 - 5 substituents, wherein each R 1 in N(R 1 ) is the same or different and is independently selected from H, 1 2 ​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0466] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n cycloalkyl, wherein n in C n is 1 - 10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0467] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is an unsubstituted C n cycloalkyl, wherein n in C n is 1 - 10, and wherein R 1 、R 6 -R 9 、W, T, Y, Z, Q and X are as defined.

[0468] One embodiment of the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n cycloalkyl substituted with 1 - 5 substituents, wherein n in C n is 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2-alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0469] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n cycloalkyl, wherein n in C n is 1-10, wherein at least one of these substituents is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1-5 substituents, wherein each R 1 in N(R 1 )(R 1 ) are the same or different and are independently selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0470] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R5 at least one of which is C n heterocycloalkyl, wherein C n in which n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0471] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is unsubstituted C n heterocycloalkyl, wherein C n in which n is 1 - 10, and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0472] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C substituted with 1 - 5 substituents n heterocycloalkyl, wherein C n in which n is 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q , and wherein R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.

[0473] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C substituted with 1 - 5 substituents n heterocycloalkyl, wherein C n in which n is 1 - 10, wherein at least one of these substituents is -C q -U-Cq , wherein -C q -U-C q each q in is independently 0 - 10, wherein U is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 1 - 5 substituents, and the substituents of each R in N(R 1 )(R 1 )(R 1 ) are the same or different and are independently selected from H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 2 、R 1 、R 6 -R 9 、W、T、Y、Z、Q and X are as defined.

[0474] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein Q is a bond, and wherein R 1 -R 9 、W、T、Y、Z and X are as defined.

[0475] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein Q is O, and wherein R 1 -R 9 、W、T、Y、Z and X are as defined.

[0476] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each part is independently selected, wherein X is C, and wherein R 1 -R 9 、W、T、Y、Z and Q are as defined.

[0477] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein X is N, and wherein R 1 -R 9 、W、T、Y、Z and Q are as defined.

[0478] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein X is O, R 6 is absent, and wherein R 1 -R 5 、R 7 -R 9 、W、T、Y、Z and Q are as defined.

[0479] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein X is S, R 6 is absent, and wherein R 1 -R 5 、R 7 -R 9 、W、T、Y、Z and Q are as defined.

[0480] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein A is unsaturated, and wherein R 1 -R 9 、W、T、Y、Z、X and Q are as defined.

[0481] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein A is saturated, and wherein R 1 -R 9 、W、T、Y、Z、X and Q are as defined.

[0482] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is a bond, and wherein R 1 -R 9 、W、T、Z、X and Q are as defined.

[0483] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is C, and wherein R 1 -R 9 、W、T、Z、X and Q are as defined.

[0484] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is N, and wherein R 1 -R 9 , W, T, Z, X, and Q are as defined.

[0485] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is O, and wherein R 1 -R 9 , W, T, Z, X, and Q are as defined.

[0486] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is an alkyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 , W, T, Z, X, and Q are as defined.

[0487] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Y is an alkenyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 , W, T, Z, X, and Q are as defined.

[0488] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein n is 0 - 3, and wherein R 1 -R 9 , W, T, Z, Y, X, and Q are as defined.

[0489] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is a bond, and wherein R 1 -R 9 , W, Y, Z, X, and Q are as defined.

[0490] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is C, and wherein R 1 -R 9 , W, Y, Z, X, and Q are as defined.

[0491] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is N, and wherein R 1 -R 9 , W, Y, Z, X, and Q are as defined.

[0492] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is O, and wherein R 1 -R 9 、W, Y, Z, X and Q are as defined.

[0493] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is an alkyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 、W, Y, Z, X and Q are as defined.

[0494] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein T is an alkenyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 、W, Y, Z, X and Q are as defined.

[0495] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is a bond, and wherein R 1 -R 9 、Y, T, Z, X and Q are as defined.

[0496] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is C, and wherein R 1 -R 9 、Y, T, Z, X and Q are as defined.

[0497] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is N, and wherein R 1 -R 9 、Y, T, Z, X and Q are as defined.

[0498] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is O, and wherein R 1 -R 9 、Y, T, Z, X and Q are as defined.

[0499] One embodiment of the present invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is an alkyl group having 1 to 4 carbon atoms, and wherein R 1 -R9 、 Y, T, Z, X, and Q are as defined.

[0500] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein W is an alkenyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 、 Y, T, Z, X, and Q are as defined.

[0501] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is a bond, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0502] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is C, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0503] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is N, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0504] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is O, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0505] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is an alkyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0506] One embodiment of the invention includes a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein Z is an alkenyl group having 1 to 4 carbon atoms, and wherein R 1 -R 9 、 W, T, Y, X, and Q are as defined.

[0507] Formula II

[0508] In another embodiment, the invention can be a compound of formula II or a pharmaceutically acceptable salt or ester thereof:

[0509]

[0510] wherein R 1 and R 6 -R 9 are independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl,

[0511] wherein the halogen is selected from -F, -Cl, -Br, -I, -At and -Ts,

[0512] wherein R a is H or alkyl,

[0513] wherein B is boron,

[0514] wherein n is 1 - 10,

[0515] wherein R 2 -R 5 are each independently -H, -CN, -COOH, -COOMe, -CONH 2 , B(OR a ) 2 , an acid isostere, a halogen, -CONHOH, -NH-SO 2 -Cι-C 6 -alkyl, -NHSO 2 Ar, C n alkyl, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl,

[0516] wherein -NHSO 2Ar in Ar is selected from phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene,

[0517] wherein C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl is each unsubstituted or substituted with 1 to 5 substituents,

[0518] wherein each substituent is the same or different,

[0519] wherein each substituent is selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl and -C q -U-C q ,

[0520] wherein each q in -C q -U-C q is independently 0 to 10,

[0521] wherein U in -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ),

[0522] wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl,n An alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl,

[0523] wherein each R in N(R 1 )(R 1 ) 1 is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents, these substituents being the same or different and independently selected from H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl,

[0524] wherein Q is a bond or O,

[0525] wherein X is C, N, O or S, and if X is O or S, then R 6 ,

[0526] wherein X is C, N, O or S, and wherein

[0527] n is 0, 1, 2 or 3.

[0528] In some embodiments, the present invention includes a compound of formula II, wherein the heterocycloalkyl is formed by bonding two of R 7 , R 8 or R 9 to form the following substances:

[0529]

[0530] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is -CN, and wherein R 2 -R 5 , Q and X are as defined.

[0531] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is -COOH, and wherein R 2 -R5 , Q, and X are as defined.

[0532] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is -CONH 2 , and wherein R 2 -R 5 , Q, and X are as defined.

[0533] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is B(OR a ) 2 , wherein B in B(OR a ) 2 is boron, wherein R a in B(OR 2 ) a is H, and wherein R 2 -R 5 , Q, and X are as defined.

[0534] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is B(OR a ) 2 , wherein B in B(OR a ) 2 is boron, wherein R a in B(OR 2 ) a is alkyl, and wherein R 2 –R 5 , Q, and X are as defined.

[0535] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is an acid isostere disclosed herein, and wherein R 2 -R 5 , Q, and X are as defined.

[0536] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is halogen, and wherein R 2 -R 5 , Q and X are as defined.

[0537] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkyl, wherein n in C n alkyl is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0538] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is unsubstituted C n alkyl, wherein n in C n alkyl is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0539] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is C n alkyl substituted with 1-5 substituents, wherein n in C n alkyl is 1-10, wherein each substituent is the same or different, and wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl or -C q -U-C q , wherein R 2 -R5 , Q, and X are as defined.

[0540] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of which is a C n alkyl group substituted with 1-5 substituents, wherein n in the C n alkyl group is 1-10, and at least one of these substituents is -C q -U-C q , wherein -C q -U-C q Each q in is independently 0-10, wherein -C q -U-C q U in is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and wherein R 2 –R 5 , Q, and X are as defined.

[0541] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 At least one of which is a C n alkyl group substituted with 1-5 substituents, wherein n in the C n alkyl group is 1-10, and at least one of these substituents is -C q -U-C q , wherein -C q -U-C q Each q in is independently 0-10, wherein -C q -U-C q U in is N(R 1 )(R 1 ), wherein each R 1 )(R 1 ) in N(R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and wherein R 2 –R 5 , Q, and X are as defined.

[0542] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is H, and wherein R 2 -R 5 , Q and X are as defined.

[0543] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is 2 H, and wherein R 2 -R 5 , Q and X are as defined.

[0544] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein the substituent is a halogen, and wherein R 2 -R 5 , Q and X are as defined.

[0545] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an amino group, and wherein R 2 -R 5 , Q and X are as defined.

[0546] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an alkoxy group, and wherein R 2 -R 5 , Q and X are as defined.

[0547] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is a cyano group, and wherein R 2 -R 5 , Q and X are as defined.

[0548] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an aminoalkyl-, and wherein R 2 -R 5 , Q and X are as defined.

[0549] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an (amino)alkoxy-, and wherein R 2 -R 5 , Q and X are as defined.

[0550] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is an -alkyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0551] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is an -alkenyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0552] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is an -alkynyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0553] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is an alkoxy-group, and wherein R 2 -R 5 , Q and X are as defined.

[0554] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in the C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one of these substituents is a hydroxyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0555] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in the C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one of these substituents is an - alkylhydroxyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0556] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in the C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one of these substituents is an aryloxy - group, and wherein R 2 -R 5 , Q and X are as defined.

[0557] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is a substituted C n alkyl, where n in the C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one of these substituents is an - alkyl(aryl) group, and wherein R 2 -R 5 , Q and X are as defined.

[0558] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an (alkoxyalkyl)amino-group, and wherein R 2 -R 5 , Q and X are as defined.

[0559] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an aryl group, and wherein R 2 -R 5 , Q and X are as defined.

[0560] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an -aryl(halo) group, and wherein R 2 -R 5 , Q and X are as defined.

[0561] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in at least one is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an -heteroaryl group, and wherein R 2 -R 5 , Q and X are as defined.

[0562] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is a hydroxy-alkyl-group, and wherein R 2 -R 5 , Q and X are as defined.

[0563] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is a hydroxy-aryl-group, and wherein R 2 -R 5 , Q and X are as defined.

[0564] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is an (aryl)alkyl-group, and wherein R 2 -R 5 , Q and X are as defined.

[0565] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, wherein at least one of these substituents is -S(O) 2 -alkyl, and wherein R 2 -R 5 , Q and X are as defined.

[0566] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is -S(O) 2 -aryl group, and wherein R 2 -R 5 , Q and X are as defined.

[0567] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is -C(O)alkyl group, and wherein R 2 -R 5 , Q and X are as defined.

[0568] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is -C q -U-C q , and wherein R 2 -R 5 , Q and X are as defined.

[0569] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one of these substituents is -C q -U-C q, wherein -C q -U-C q each q in is independently 0 - 10, wherein U is a heteroaryl, and wherein R 2 -R 5 , Q and X are as defined.

[0570] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein U is a cycloalkyl, and wherein R 2 -R 5 , Q and X are as defined.

[0571] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, wherein U is a heterocycloalkyl, and wherein R 2 -R 5 , Q and X are as defined.

[0572] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-Cq each q in is independently 0 - 10, where U is O, and where R 2 -R 5 , Q and X are as defined.

[0573] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, where U is S, and where R 2 -R 5 , Q and X are as defined.

[0574] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-C q each q in is independently 0 - 10, where U is SO 2 , and where R 2 -R 5 , Q and X are as defined.

[0575] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of is a substituted C n alkyl, wherein n in C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein -C q -U-C qEach q in is independently 0 - 10, where U is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and where R n –R 2 –R 5 、Q and X are as defined.

[0576] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where at least one of R 1 and R 6 –R 9 is a substituted C n alkyl, where n in C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R n in N(R 1 )(R 1 ) is unsubstituted, and where R 1 –R 2 –R 5 、Q and X are as defined.

[0577] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, where each moiety is independently selected, where at least one of R 1 and R 6 –R 9 is a substituted C n alkyl, where n in C n alkyl is 1 - 10, where the number of substituents is 1 - 5, where at least one substituent is -C q -U-C q, wherein -C q -U-C q Each q in is independently 0 - 10, wherein U is N(R 1 )(R 1 ), wherein each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R n )(R 1 )(R 1 ) is substituted with 1 - 5 substituents, wherein each substituent is the same or different, and each substituent is H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 2 -R 2 -R 5 , Q and X are as defined.

[0578] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is C n alkyl substituted with 1 - 5 identical or different substituents, wherein n in C n alkyl is 1 - 10, and wherein R 2 -R 5 , Q and X are as defined.

[0579] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 1 and R 6 -R 9 is unsubstituted or C n alkenyl substituted with 1 - 5 identical or different substituents, wherein n in C n alkenyl is 1 - 10, and wherein R 2 -R 5 , Q and X are as defined.

[0580] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is an unsubstituted or C n aryl substituted with 1-5 identical or different substituents, wherein C n in the aryl, n is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0581] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is an unsubstituted or C n aminoalkyl substituted with 1-5 identical or different substituents, wherein C n in the aminoalkyl, n is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0582] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is an unsubstituted or C n haloalkyl substituted with 1-5 identical or different substituents, wherein C n in the haloalkyl, n is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0583] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 at least one of which is an unsubstituted or C n heteroaryl substituted with 1-5 identical or different substituents, wherein C n in the heteroaryl, n is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0584] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is an unsubstituted or C n cycloalkyl substituted with 1-5 identical or different substituents, wherein n in C n cycloalkyl is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0585] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 1 and R 6 -R 9 in which at least one is an unsubstituted or C n heterocycloalkyl substituted with 1-5 identical or different substituents, wherein n in C n heterocycloalkyl is 1-10, and wherein R 2 -R 5 , Q and X are as defined.

[0586] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in which at least one is -H, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0587] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in which at least one is -CN, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0588] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in which at least one is -COOH, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0589] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -COOMe, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0590] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -CONH 2 ,and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0591] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is B(OR a ) 2 ,wherein B is boron, wherein R a is H, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0592] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is B(OR a ) 2 ,wherein B is boron, wherein R a is alkyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0593] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is an acid isostere, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0594] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a halogen, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0595] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -CONHOH, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0596] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NH-SO 2 -Cι-C 6 -alkyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0597] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is phenyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0598] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is naphthyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0599] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2-R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrrole, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0600] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is imidazole, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0601] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is thiophene, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0602] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isothiazole, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0603] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is thiadiazole, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0604] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5at least one of which is -NHSO 2 Ar, where Ar is oxazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0605] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoxazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0606] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is oxadiazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0607] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyridine, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0608] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrazine, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0609] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein R 2 -R 5 at least one of which is -NHSO 2Ar, where Ar is pyrimidine, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0610] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyridazine, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0611] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is pyrazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0612] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is triazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0613] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is tetrazole, and where R 1 、R 6 -R 9 、Q and X are as defined.

[0614] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is chroman, and where R1 , R 6 -R 9 , Q, and X are as defined.

[0615] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isochroman, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0616] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinoline, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0617] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinoxaline, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0618] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoquinoline, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0619] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is phthalazine, and wherein R 1 , R6 -R 9 、Q and X are as defined.

[0620] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is cinnoline, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0621] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is quinazoline, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0622] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indole, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0623] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is isoindole, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0624] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indoline, and wherein R 1 、R 6 -R9 、Q and X are as defined.

[0625] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is isoindoline, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0626] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is benzothiophene, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0627] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is benzofuran, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0628] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is isobenzofuran, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0629] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, wherein Ar is benzoxazole, and wherein R 1 、R 6 -R 9, Q, and X are as defined.

[0630] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzoxadiazole, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0631] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzothiazole, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0632] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzothiadiazole, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0633] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 2,1,3-benzoselenadiazole, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0634] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzimidazole, and wherein R 1 , R 6 -R9 , Q, and X are as defined.

[0635] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indazole, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0636] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is benzodioxane, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0637] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is indane, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0638] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0639] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 3,4-dihydro-2H-1,4-benzoxazine, and wherein R 1 , R 6-R 9 , Q, and X are as defined.

[0640] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,5-naphthyridine, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0641] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is 1,8-naphthyridine, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0642] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is acridine, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0643] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is phenazine, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0644] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is -NHSO 2 Ar, where Ar is xanthene, and wherein R 1 , R 6 -R 9, Q, and X are as defined.

[0645] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of which is unsubstituted C n Alkyl, where n is 1 - 10, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0646] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of which is C alkyl substituted with 1 - 5 identical or different substituents, wherein each substituent is H, n H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, where n in C alkyl is 1 - 10, and wherein R 2 n 1 , R 6 , R 9 -R 2 , Q, and X are as defined.

[0647] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of which is substituted C alkyl, wherein the number of substituents is 1 - 5, and at least one substituent is -C n -U-C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), where n in C alkyl is 1 - 10, and wherein R n 1 , R 6 , R -R9 , Q, and X are as defined.

[0648] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of which is a C n alkyl group substituted with 1-5 identical or different substituents, wherein at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein n in C n alkyl is 1-10, and wherein R 1 , R 6 -R 9 , Q, and X are as defined. One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of which is a substituted C n alkyl group, wherein n in C n alkyl is 1-10, wherein the number of substituents is 1-5, wherein at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is unsubstituted, and wherein R 1 , R6 -R 9 , Q, and X are as defined.

[0649] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkyl, wherein n in the C n alkyl is 1 - 10, wherein the number of substituents is 1 - 5, and wherein at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, wherein U is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 - 5 identical or different substituents, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0650] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is an unsubstituted C n alkenyl, wherein n in the C n alkenyl is 1 - 10, and wherein R 1 , R 6 -R 9, Q, and X are as defined.

[0651] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkenyl, wherein n in the C n alkenyl is 1-10, wherein the number of substituents is 1-5 identical or different substituents, and each substituent is: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0652] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a C n alkenyl substituted with 1-5 substituents, wherein n in the C n alkenyl is 1-10, and at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and U in -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0653] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a Cn Alkenyl, wherein C n In the alkenyl, n is 1 - 10, and at least one substituent is -C q -U-C q , wherein -C q -U-C q In each q is independently 0 - 10, wherein -C q -U-C q In U is N(R 1 )(R 1 ), wherein in N(R 1 )(R 1 ) each R 1 is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein in N(R 1 )(R 1 ) each R 1 is substituted with 1 - 5 substituents, wherein in N(R 1 )(R 1 ) each R 1 's substituents are the same or different and are independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0654] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and wherein at least one of R 2 -R 5 is C n alkynyl, wherein in C n alkynyl n is 1 - 10, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0655] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is an unsubstituted C n alkynyl, wherein n in the C n alkynyl is 1-10, wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0656] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a C n alkynyl substituted with 1-5 identical or different substituents, wherein n in the C n alkynyl is 1-10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0657] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkynyl, wherein n in the C n alkynyl is 1-10, wherein the number of substituents is 1-5, wherein each substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 to 10, wherein U in -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and wherein R 1, R 6 -R 9 , Q and X are as defined.

[0658] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is a substituted C n alkynyl, wherein n in the C n alkynyl is 1 - 10, wherein the number of substituents is 1 - 5, and each substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 - 10, and U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R 1 in N(R 1 )(R 1 ) is substituted with 1 - 5 substituents, and the substituents of each R 1 in N(R 1 )(R 1 ) are the same or different and are independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0659] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is Cn aryl, wherein C n in the aryl, n is 1 - 10, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0660] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is an unsubstituted C n aryl, wherein C n in the aryl, n is 1 - 10, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0661] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n aryl substituted with 1 - 5 identical or different substituents, wherein C n in the aryl, n is 1 - 10, and each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0662] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n aryl substituted with 1 - 5 identical or different substituents, wherein C n in the aryl, n is 1 - 10, and at least one substituent is -C q -U-C q , wherein -C q -U-C qeach q in is independently 0 - 10, where -C q -U-C q U in is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.

[0663] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is a C n aryl substituted with 1 - 5 identical or different substituents, where n in C n aryl is 1 - 10, and wherein at least one substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, where -C q -U-C q U in is N(R 1 )(R 1 ), where each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R 1 in N(R 1 )(R 1 ) is substituted with 1 - 5 substituents, where each R 1 in N(R 1 )(R 1 ) has the same or different substituents and is independently selected from: H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and where R 1 , R6 -R 9 , Q, and X are as defined.

[0664] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C n aminoalkyl, wherein n in C n aminoalkyl is 1 - 10, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0665] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is unsubstituted C n aminoalkyl, wherein n in C n aminoalkyl is 1 - 10, wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0666] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 at least one of which is C n aminoalkyl substituted with 1 - 5 identical or different substituents, wherein n in C n aminoalkyl is 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q, and X are as defined.

[0667] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5At least one of them is C substituted by 1 to 5 identical or different substituents. n Aminoalkyl, where C n The n in the aminoalkyl group is 1-10, and at least one of the substituents is -C q -UC q , where -C q -UC q Each q in is independently 0-10, wherein -C q -UC q U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ) where R 1 、R 6 -R 9 , Q and X are as defined.

[0668] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 At least one of them is C substituted by 1-5 identical or different substituents n Aminoalkyl, where C n The n in the aminoalkyl group is 1-10, and at least one of the substituents is -C q -UC q , where -C q -UC q Each q in is independently 0-10, wherein -C q -UC q U is N(R 1 )(R 1 ), where N(R 1 )(R 1 ) in each R 1 Independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where N(R 1 )(R 1 ) in each R 1 Substituted by 1-5 substituents, where N(R 1 )(R 1 ) in each R 1 The substituents of are the same or different and are independently selected from H, 2 ​​​​​​​​​​​​​​​​​H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0669] One embodiment of the invention comprises a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n haloalkyl, wherein n in the C n haloalkyl is 1 - 10, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0670] One embodiment of the invention comprises a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is unsubstituted C n haloalkyl, wherein n in the C n haloalkyl is 1 - 10, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0671] One embodiment of the invention comprises a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n haloalkyl substituted with 1 - 5 identical or different substituents, wherein n in the C n haloalkyl is 1 - 10, wherein each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2-alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0672] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n haloalkyl substituted with 1-5 identical or different substituents, wherein n in the C n haloalkyl is 1-10, and wherein at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and wherein U in -C q -U-C q is any of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and wherein R 1 、R 6 -R 9 、Q and X are as defined.

[0673] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 2 -R 5 is C n haloalkyl substituted with 1-5 identical or different substituents, wherein n in the C n haloalkyl is 1-10, and wherein at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0-10, and wherein U in -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 in N(R 1 )(R 1 ) is independently hydrogen, C n alkyl, C n alkenyl, C nAlkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R in N(R 1 )(R 1 ) is substituted with 1-5 substituents, wherein each R in N(R 1 )(R 1 ) is the same or different and independently selected from: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 1 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 2 , R 2 -R 1 , Q and X are as defined.

[0674] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 6 -R 9 is C 2 heteroaryl, wherein n in C 5 heteroaryl is 1-10, and wherein R n , R n -R 1 , Q and X are as defined.

[0675] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 6 -R 9 is unsubstituted C 2 heteroaryl, wherein n in C 5 heteroaryl is 1-10, and wherein R n , R n -R 1 , Q and X are as defined.

[0676] One embodiment of the invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein at least one of R 6 -R 9 is C 2 heteroaryl substituted with 1-5 identical or different substituents, wherein n in C 5 heteroaryl is 1-10, and wherein R n heteroaryl, wherein C nn in the heteroaryl is 1 - 10, where each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and where R 1 , R 6 -R 9 , Q and X are as defined.

[0677] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where at least one of R 2 -R 5 is a C n heteroaryl substituted with 1 - 5 identical or different substituents, where n in the C n heteroaryl is 1 - 10, and where at least one substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and where U in -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.

[0678] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where at least one of R 2 -R 5 is a C n heteroaryl substituted with 1 - 5 identical or different substituents, where n in the C n heteroaryl is 1 - 10, and where at least one substituent is -C q -U-C q , where each q in -C q -U-C q is independently 0 - 10, and where -C q -U-C qwherein U is N(R 1 )(R 1 ) and each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, and each R in N(R n )(R 1 )(R 1 ) is substituted with 1-5 substituents, and the substituents of each R in N(R 1 )(R 1 )(R 1 ) are the same or different and are independently selected from: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and wherein R 2 1 , R 6 -R 9 2 , Q and X are as defined.

[0679] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and at least one of R 2 -R 5 is C n cycloalkyl, where n in C n cycloalkyl is 1-10, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0680] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, and at least one of R 2 -R 5 is unsubstituted C n cycloalkyl, where n in C n cycloalkyl is 1-10, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0681] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in at least one is a C n cycloalkyl substituted with 1 to 5 identical or different substituents, wherein the n in C n cycloalkyl is 1 to 10, and each substituent is H, 2 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl or -C(O)alkyl, and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0682] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in at least one is a C n cycloalkyl substituted with 1 to 5 identical or different substituents, wherein the n in C n cycloalkyl is 1 to 10, and at least one substituent is -C q -U-C q , wherein each q in -C q -U-C q is independently 0 to 10, and U in -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 or N(R 1 )(R 1 ), and wherein R 1 , R 6 -R 9 , Q and X are as defined.

[0683] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, wherein each moiety is independently selected, wherein R 2 -R 5 in at least one is a C n cycloalkyl substituted with 1 to 5 identical or different substituents, wherein the Cn In the cycloalkyl group, n is 1 - 10, and at least one substituent is -C q -U-C q , where -C q -U-C q each q in is independently 0 - 10, where -C q -U-C q in U is N(R 1 )(R 1 ), where each R in N(R 1 )(R 1 ) is independently hydrogen, C 1 alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, where each R in N(R n )(R 1 )(R 1 ) is substituted with 1 - 5 substituents, where each R in N(R 1 )(R 1 )(R 1 ) has the same or different substituents and is independently selected from: H, 1 H, halogen, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxy-alkyl-, hydroxy-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl and -C(O)alkyl, and where R 2 , R 1 , R 6 -R 9 , Q and X are as defined.

[0684] One embodiment of the present invention includes a compound of formula (II) or a pharmaceutically acceptable salt or ester thereof, where each part is independently selected, and where at least one of R 2 -R 5 is C n heterocycloalkyl, where n in C n heterocycloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and...

Claims

1. A compound of formula I comprising the following formula or a pharmaceutically acceptable salt or ester thereof: in R 1 is selected from the group consisting of fluorophenyl, morpholinyl, pyridinyl, hydrogen, halogen, benzoic acid, difluoropiperidinyl, difluoropyrrolidinyl, methylpyridinyl, dimethyloxazolyl, cyanophenyl, phenyl, hydroxyphenyl, methylphenyl and carbamoylphenyl; R 2 For hydrogen, R 3 is selected from the group consisting of hydrogen, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, fluorophenyl, pentylamino, pentyloxy, bromine, chlorine, hex-1-enyl, styryl, propylphenyl, phenylpropyl, benzyloxy, methoxy, methylstyryl, pyridine-ethyl, chlorostyryl, morpholine-vinyl, methylpiperazine-vinyl, methoxystyryl, phenyl, pyrazine-vinyl, pyrimidine-vinyl, quinoxaline-vinyl, tetrahydroquinoxaline-vinyl, quinoline-vinyl, tetrahydroquinoline-vinyl, pyrrolopyridine-vinyl, benzothiazole-vinyl, benzoxazole-vinyl, benzodiazol-vinyl, methylbenzodiazol-vinyl, methylphenylamino-vinyl, tetrahydroisoquinoline-vinyl, dihydroindoline-vinyl, hydroxypiperidinyl, pyrrolidine-vinyl, diethylaminoethyl and dihydroisoindoline-vinyl, R 4 is selected from hydrogen, bromine and hexyl, R 5 For hydrogen, R 6 is selected from hydrogen, methyl, ethyl and cyclopropyl, R 7 , R 8 and / or R 9 are independently selected from hydrogen, methyl, ethyl, propyl, formic acid, acetic acid, propionic acid, butyric acid, isopropyl, 2-methylpropyl, 2-methylpropionic acid, methylamino-acetamido-acetic acid, tetrazolyl, 1,3-thiazolidine-2,4-dione and hydroxyethyl-acetamido, wherein R 7 , R 8 and / or R 9 At least one of them is not hydrogen, Or, R 7 , R 8 or R 9 With R 6 fused to form a cycloalkyl, heteroaryl or heterocyclic group, R 6 is selected from piperidinyl, morpholinyl, pyrrolidinyl, azetidinyl, cyclopropyl, oxopyrrolidinyl, imidazolyl, pyrrolyl, methylpyrrolidinyl and 5-oxopyrrolidinyl; Q is a bond or O; X is C, N or O, and if X is O, then R is absent. 6 ; Where "A" is due to A saturated or unsaturated ring represented by, and Y, T, W and Z are independently C, and n is 0, 1, 2 or 3.

2. The compound according to claim 1, wherein R 7 , R 8 and R 9 At least one of them is related to R 6 The bonds form a fused heteroaryl group or a fused heterocycloalkyl group.

3. The compound according to claim 1, wherein R 3 C n Alkyl, and wherein n is 3-7.

4. The compound according to claim 1, wherein R 1 It is a halogen.

5. The compound of claim 1, wherein Q comprises a bond.

6. A compound selected from: 3-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-3-methyl-4-(morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexyl-3-methylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4,6-bis( 4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](2-methylpropyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](propyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl]amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-hexylquinolin-2-yl]amino}acetic acid, 2-{[6-hexyl-4-(pyridin-3-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(pyridin-4-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[ 4-(3-fluorophenoxy)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenoxy)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](2-methylpropyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](propyl)amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-octylquinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-4-yloxy)quinolin-2-yl] acetic acid, 2-{[4-(3-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-decyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-heptylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-[(6-hexylquinolin-2-yl)(methyl)amino]acetic acid, 2-{2-[(carboxymethyl)(methyl)amino]-6-hexylquinolin-4-yl}benzoic acid,2-{[4-(4,4-difluoropiperidin-1-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3,3-difluoropyrrol-1-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-methyl-pyridin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3,5-dimethyl-1,2-oxazol-4-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{ [4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}butyric acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-[methyl(6-pentylamino-4-phenylquinolin-2-yl)amino]acetic acid, 2-{methyl[6-(pentyloxy)-4-phenylquinolin-2-yl]amino}acetic acid, 2-[(7-bromo-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[(7-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}- 2-methylpropionic acid, 2-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl]oxy}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropionic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 1-[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl]piperidine-3-carboxylic acid, 1-(6-hexyl-4-phenylquinolin-2-yl)piperidine-3-carboxylic acid, 2-{[6-butyl-4-(4-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid,2-{[6-butyl-4-(2-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(pyridin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 6-butyl-2-(carboxymethoxy)-4-phenylquinoline-3-carboxylic acid, 2-{[6-butyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}acetic acid, 1-[6-butyl-4-(3-cyanophenyl)quinolin-2-yl]piperidine-3-carboxylic acid, 4-(6- 1-(6-butyl-4-phenylquinolin-2-yl)morpholine-2-carboxylic acid, 1-(6-butyl-4-phenylquinolin-2-yl)piperidine-3-carboxylic acid, 3-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-{[6-butyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]butyric acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]propanoic acid, N-(6-butyl-4-(3-cyanophenyl)quinolin-2-yl 2-{[4-(3-cyanophenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-ethylquinolin-2-yl]oxy}acetic acid, 2-{[6-bromo-4-(3-cyanophenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-bromo-4-(3-carbamoylphenyl)quinolin-2-yl]oxy}acetic acid, 2-{[ 6-butyl-4-(3-cyanophenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl]oxy}acetic acid, 2-{[4-(3-cyanophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid,2-{[4-(3-carbamoylphenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-bromo-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-bromo-4-(3-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]acetamido}acetic acid, 2-[methyl(6-pentyl-4-phenylquinolin-2-yl)] -2-yl)amino]acetic acid, 2-[methyl(4-phenyl-6-propylquinolin-2-yl)amino]acetic acid, 2-[(6-ethyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 1-(6-hexyl-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 6-hexyl-4-phenyl-2-(piperidin-1-yl)quinoline, 2-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 1-(6-butyl-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 6-butyl-4-phenyl-2-(piperidin-1-yl)quinoline, 2-[(6-bromo-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-bromo-4-phenylquinoline-2 -yl)(methyl)amino]acetic acid, 2-[(6-pentyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(4-phenyl-6-propylquinolin-2-yl)oxy]acetic acid, 2-[(6-ethyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 1-(6-chloro-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]propionic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)oxy]acetic acid 6-chloro-4-phenyl-2-(piperidin-1-yl)quinoline, 3-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 2-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[methyl[6-octyl-4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{[6-butyl-4-(3-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid,2-{[4-(4-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-{[6-decyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[methyl(4-phenyl-6-propylquinolin-2-yl)amino]acetic acid, 2-{[6-butyl-4-(4-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)- 6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(pyridin-3-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-[methyl(6-pentyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin -2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-[methyl({6-[2-(4-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid, 2-[methyl({6-[2-(3-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid , 6-hexyl-N-methyl-4-phenyl-N-[(2H-1,2,3,4-tetrazol-5-yl)methyl]quinolin-2-amine, 2-{methyl[4-phenyl-6-(2-phenylethyl)quinolin-2-yl]amino}acetic acid, 2-({6-[2-(3-chlorophenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 5-{[4-phenyl-6-(2-phenylethyl)quinolin-2-yl]methyl}-1,3-thiazolidine-2,4-dione, 2-({6-[2-(4-chlorophenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-[methyl({4-phenyl-6-[2-(pyridin-3-yl)ethyl]quinolin-2-yl})amino]acetic acid,2-[methyl({4-phenyl-6-[2-(quinolin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[(6-heptyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl({6-[2-(2-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid, 2-[methyl({4-phenyl-6-[2-(pyridin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, cis-2-(6-hexyl) 1-(6-hexyl-4-phenylquinolin-2-yl)-3-methylpyrrolidine-3-carboxylic acid, 2-[methyl({4-phenyl-6-[2-(pyrimidin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[(6-hexyl-4-phenyl-5,6,7,8-tetrahydroquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl({4-phenyl-6-[2-(quinoxalin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid 2-{6-[(1E)-hex-1-en-1-yl]-4-phenylquinolin-2-yl}(methyl)amino]acetic acid, 2-{methyl[4-phenyl-6-(3-phenylpropyl)quinolin-2-yl]amino}acetic acid, 2-[methyl({4-phenyl-6-[2-(1,2,3,4-tetrahydroquinolin-6 -yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-({6-[2-(3-methoxyphenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-({6-[2-(1,3-benzothiazol-2-yl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-{[6-hexyl-4-(pyridin-4-yl)quinolin-2-yl]oxy}propanoic acid and 3-(6-hexyl-4-phenylquinolin-2-yl)butanoic acid.

7. Use of the compound of claim 1 in the preparation of a medicament for inhibiting mammalian fatty acid binding protein FABP4, comprising administering an effective amount of the compound of claim 1 to a mammal; wherein the disease associated with the inhibition of mammalian fatty acid binding protein FABP4 is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis, and non-alcoholic steatohepatitis.

8. The use according to claim 7, wherein the disease associated with the inhibition of mammalian fatty acid binding protein FABP4 is selected from hyperglycemia and intracranial atherosclerotic disease.

9. The use according to claim 7, wherein the subject is a human.

10. Use of the compound of claim 1 in the preparation of a medicament for preventing or treating a disease acting on the fatty acid binding protein FABP4, wherein the disease is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis, and non-alcoholic steatohepatitis.

11. The use according to claim 10, wherein the disease is selected from hyperglycemia and intracranial atherosclerotic disease.

12. A pharmaceutical composition comprising the compound of claim 1 as an active ingredient.

13. The pharmaceutical composition according to claim 12, further comprising at least one additional active ingredient or a pharmaceutically acceptable carrier.

14. Use of the compound of claim 1 in the preparation of a medicament for preventing or treating a disease acting on the fatty acid binding protein FABP4, comprising administering an effective amount of the compound of claim 1 to a subject in need of such treatment, wherein the disease is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis, and non-alcoholic steatohepatitis.

15. Use according to claim 14, wherein the disease is selected from hyperglycemia and intracranial atherosclerotic disease.

16. The use according to claim 14, wherein the subject is a human.

17. Use of the compound of claim 6 in the preparation of a medicament for inhibiting mammalian fatty acid binding protein FABP4, comprising administering an effective amount of the compound of claim 6 to a mammal; wherein the disease associated with the inhibition of mammalian fatty acid binding protein FABP4 is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis and non-alcoholic steatohepatitis.

18. The use according to claim 17, wherein the disease associated with the inhibition of mammalian fatty acid binding protein FABP4 is selected from hyperglycemia and intracranial atherosclerotic disease.

19. The use according to claim 17, wherein the subject is a human.

20. Use of the compound of claim 6 in the preparation of a medicament for preventing or treating a disease acting on the fatty acid binding protein FABP4; wherein the disease is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis and non-alcoholic steatohepatitis.

21. The use according to claim 20, wherein the disease is selected from hyperglycemia and intracranial atherosclerotic disease.

22. A pharmaceutical composition comprising the compound of claim 6 as an active ingredient.

23. The pharmaceutical composition according to claim 22, further comprising at least one additional active ingredient or a pharmaceutically acceptable carrier.

24. Use of the compound of claim 6 in the preparation of a medicament for preventing or treating a disease acting on the fatty acid binding protein FABP4, comprising administering an effective amount of the compound of claim 6 to a subject in need of such treatment; wherein the disease is selected from type 2 diabetes, metabolic syndrome, obesity, atherosclerosis and non-alcoholic steatohepatitis.

25. Use according to claim 24, wherein the disease is selected from hyperglycemia and intracranial atherosclerotic disease.

26. The use according to claim 24, wherein the subject is a human.

Images